Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Unicycive Therapeutics, Inc.

NASDAQ: UNCY · Life Sciences · 4 alerts · CIK 1766140

Share price
$3.70Close, Nov 16
Market cap
$108M
Shares outstanding
29.18MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Unicycive Therapeutics, Inc. filings on SEC EDGAR ↗

9:29 AM ET 8-K
Financial Results

Unicycive Therapeutics Financial Results

Unicycive Therapeutics reported third quarter 2026 financial results and provided a business update regarding its New Drug Application (NDA) for oxylanthanum carbonate (OLC). The FDA has accepted the NDA resubmission with a PDUFA target action date of March 25, 2027, following a previous Complete Response Letter related to manufacturing vendor deficiencies.

“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients. With a PDUFA target action date of March 25, 2027, our focus now is on continuing to advance launch preparations in parallel with the FDA’s review in order to support a potential launch.”

Shalabh Gupta, M.D., Chief Executive Officer
6:32 AM ET 10-Q
Financial Results

Unicycive Therapeutics Q3 2026 Results: Net Loss of $7M, Loss Widens

Unicycive Therapeutics reported a net loss of $7.0 million for the quarter ended September 30, 2026, compared to $6.0 million in the prior year period. The company's cash position strengthened to $42.0 million, supported by $39.0 million in net proceeds from financing activities during the first nine months of 2026.

Key figure
Net loss $7M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.